Vaccination of patients with primary immunodeficiencies: a modern view on the problem


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Vaccination in patients with primary immunodeficiencies (PID) remains a subject of serious discussion. 20 years ago it was thought that vaccination could cause unacceptable harm to patients’ with PID, so immunization with any vaccine was strictly prohibited. Later this position was softened, when it had turned out that the risk of adverse events developing for most of the vaccines patients with PID is not higher than of the rest population. Nevertheless, it was supposed that immunization of these patients was useless because of patients’ inability to form a post-vaccination immunity. Only for the last 10 years due to new researches and accumulated experience an attitude towards vaccination in patients with PID has been radically changed. Nowadays there is only a small range of vaccines is strictly prohibited to use, while immunization against some infections is strongly recommended by the world community.

作者简介

T Latysheva

Institute of Immunology

Email: tvlat@mail.ru

E Latysheva

Institute of Immunology

I Manto

Institute of Immunology

A Kostinova

Institute of Immunology

参考

  1. Аллергология и иммунология. Национальное руководство, краткое издание. Под ред. Р.М. Хаитова и Н.И. Ильиной. М., «Гэотар-медиа». 2013, с. 300-386.
  2. Chapel H. Primary Immune Deficiencies - Principles of Care. Front. Immunol. 2014, v. 5, p. 627.
  3. Al-Herz W., Bousfiha A., Casanova J.L. et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front. Immunol. 2014, v. 5, p. 162.
  4. Bonilla F.A., Khan D.A., Ballas Z.K. et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J. Allergy Clin. Immunol. 2015, v. 136, p. 1186-1205.
  5. Papadopoulou-Alataki E., Hassan A., Davies E.G. Prevention of infection in children and adolescents with primary immu nodeficiency disorders. Asian Pac. J. Allergy Immunol. 2012, v. 30, p. 249-258.
  6. Frenzel W., Wietek S., Svae T.E. et al. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trial. Int. J. Clin. Pharmacol. Ther. 2016, v. 54, p. 847-855.
  7. Аллергология и иммунология. Национальное руководство, краткое издание. Под ред. Р.М. Хаитова и Н.И. Ильиной. М., «Гэотар-медиа». 2013, с. 152-155.
  8. Медуницын Н.В. Вакцинология. «Триада Х». М., 2010, с. 288-290.
  9. Eibl M.M., Wolf H.M. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. Immunotherapy. 2015, v. 7, p. 1273-1292.
  10. Principi N., Esposito S. Vaccine use in primary immunodeficiency disorders. Vaccine. 2014, v. 32, p. 3725-3731.
  11. Goldacker S., Draeger R., Warnatz K. et l. Active vaccination in patients with common variable immunodeficiency (CVID). Clin. Immunol. 2007, v. 124, p. 294-303.
  12. Canadian Immunization Guide, Seventh Edition - 2006, Text prepared by the National Advisory Committee on Immunization Published by the Public Health Agency of Canada Infectious Disease and Emergency Preparedness Branch Centre for Infectious Disease Prevention and Control under the authority of the Minister of Public Works and Government Services Canada, p. 117-130.
  13. Rubin L.G., Levin M.J., Ljungman P. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Infect. Dis. 2014, v. 58, p. 44-100.
  14. Shearer W.T., Fleisher T.A., Buckley R.H. et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close-contacts: Medical Advisory Committee of the Immune Deficiency Foundation. The Journal of Allergy and Clinical Immunology. 2014, v. 133, p. 961-966.
  15. Marciano B.E., Huang C.Y., Joshi G. et al. BCG vaccination in SCID patients: complications, risks and vaccination policies. The Journal of allergy and clinical immunology. 2014, v. 133, p. 1134-1141.
  16. Shaghaghi M., Shahmahmoodi S., Abolhassani H. et al. Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995-2014. Emerging Infectious Diseases. 2016, v. 22, p. 1712-1719.
  17. Shaghaghi M., Parvaneh N., Ostad-Rahimi P. et al. Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature. Immunol Invest. 2014, v. 43, p. 292-298.
  18. Shahmahmoodi S., Mamishi S., Aghamohammadi A. et al. Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995-2008. Emerg. Infect. Dis. 2010, v. 16, p. 1133-1136.
  19. Parvaneh N., Shahmahmoudi S., Tabatabai H. et al. Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency. J. Clin. Virol. 2007, v. 39, p. 145-148.
  20. Conti F., Lugo-Reyes S.O., Blancas Galicia L. et al. Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases. J. Allergy Clin. Immunol. 2016, v. 138, p. 241-248.
  21. Saul L.R., Lizbeth B.G., Jacinta B. 135 Mycobacterial Infections in cChildren With Chronic Granulomatous Disease World Allergy Organization Journal. 2012, v. 5, p. 62.
  22. Goldacker S., Draeger R., Warnatz K. et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin. Immunol. 2007, v. 124, p. 294-303.
  23. Pedersen G., Halstensen A., Sjursen H. et al. Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports. Scand. J. Immunol. 2011, v. 74, p. 210-218.
  24. Rezaei N., Siadat S.D., Aghamohammadi A. et al. Serum bactericidal antibody response 1 year after meningococcal polysaccharide vaccination of patients with common variable immunodeficiency. Clin. Vaccine Immunol. 2010, v. 17, p. 524-528.
  25. Hanitsch L.G., Löbel M., Mieves J.F. et al. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency. Vaccine. 2016, v. 5, p. 2417-2423.
  26. Paroli M., Accapezzato D., Francavilla V. et al. Long-lasting memory-resting and memory-effector CD4+ T-cells in human X-linked agammaglobulinemia. Blood. 2002, v. 99, p. 2131-2137.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Pharmarus Print Media, 2017

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).